Navigation Links
Bypass Surgery, Drug-eluting Stents Possess Similar Risk and Outcome

Drug-eluting stent therapy and bypass surgery for coronary artery disease have about the same risk for a major cardiac event within 30 days after the procedures// , according to researchers.

The two also have similar outcomes three years after treatment. Patients with coronary arteries narrowed by atherosclerosis are often candidates for either bypass surgery to reroute the arteries' blood flow or a stent, which is a small mesh tube that helps keep arteries open after angioplasty, a procedure to open clogged arteries.

Previous studies have found that placing bare-metal stents is safer than bypass surgery. However, "bypass surgery is much more successful for restoring patients' blood flow in the long-term because arteries with traditional stents re-narrow in about one out of every three cases," said James M. Wilson, M.D., senior author of the study. The newer drug-eluting stents were developed to help keep arteries open longer, but until now their effectiveness had not been compared with the gold standard bypass surgery.

Wilson and colleagues analyzed 799 drug-eluting stent patients and 799 coronary bypass patients, comparing how they fared in the first 30 days after their procedures and during the next three years.

"What we found came as a bit of a surprise," said Wilson, program director of the Cardiology Fellowship Program at St. Luke's Episcopal Hospital and Texas Heart Institute in Houston. "We found that the likelihood of any complication in the hospital was the same whether you had a drug-eluting stent or bypass. Five percent of drug-eluting stent patients had some major complication in the hospital, mostly heart attack, as opposed to about 3.8 percent of the patients who had bypass. Those numbers, although seemingly different, are statistically the same."

"We have done further research since comparing drug-eluting to bare-metal stents and have found that the higher complication rate among drug-e luting patients is not due to the technology but rather patient selection," said Wilson, who is also assistant chief of cardiology at St. Luke's Episcopal Hospital. "Now that we have more confidence in the long-term effectiveness of the drug-eluting stents, we are using the technology on much sicker patients."

Drug-eluting stents were better than bare-metal stents when compared to bypass surgery in terms of survival, with no statistically significant difference between the drug-eluting stents and bypass groups. Researchers reported that the death rate at three years with bypass was 6.6 percent and 9 percent after drug-eluting stent therapy.

The research suggests that if doctors use drug-eluting stents in patients who are lower risk, they might expect even more favorable results, said Muhammad S. Munir, M.D., lead author of the study and a nonclinical research fellow at the Texas Heart Institute.

"If the patient selection is made less aggressively or more optimally, it may give drug-eluting stents better results in the long run, making drug-eluting stents emerge as a treatment that would be better than all other contemporary methods," Munir said.

Wilson said it's best, "sticking to what we do well. We have reported that the risk of bypass surgery and drug-eluting stents is the same among high-risk patients. So, if we choose the patients we know we can treat well with stents, then it is reasonable to treat them by a catheter rather than by surgery. If we can't do a good job with stents, then bypass is the better choice."

Source-Eurekalert
'"/>




Related medicine news :

1. Bypass Heart Surgery Performed Without General Anesthesia
2. Older Men Surviving Coronary Bypasses
3. Bypass Surgery & Pleural Effusion
4. Life after Bypass not so Promising for Women.
5. The Reason For Loss Of Appetite After Gastric Bypass
6. Bypassing open heart bypass surgery...
7. Surgeons Perform Robotic Gastric Bypass Surgery
8. Poor Andhra Women Enable Bypass Surgery Paying 50 Paise Each
9. Prayers Do Not Help Healing Process In Bypass Patients
10. Gastric Bypass And Laparoscopic Reflux Surgery Gaining Popularity
11. For Super-Obese Patients, Duodenal Switch Beats Gastric Bypass
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology: